Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del(17p)

被引：0
|
作者：
Jain, Nitin [1 ]
Thompson, Philip [1 ]
Burger, Jan A. [1 ]
Borthakur, Gautam [1 ]
Bose, Prithviraj [1 ]
Estrov, Zeev [1 ]
Ferrajoli, Alessandra [1 ]
Gandhi, Varsha [1 ]
Plunkett, William [1 ]
Lopez, Wanda [1 ]
Kantarjian, Hagop [1 ]
O'Brien, Susan [2 ]
Keating, Michael [1 ]
Wierda, William [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif, Chao Family Comprehens Canc Ctr, Orange, NJ USA
[3] Univ Texas, Houston, TX USA
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
164
引用
收藏
页码：158 / 159
页数：2
相关论文
共 50 条
  • [21] Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
    Huber, Henriette
    Tausch, Eugen
    Schneider, Christof
    Edenhofer, Simone
    Von Tresckow, Julia
    Robrecht, Sandra
    Giza, Adam
    Zhang, Can
    Furstenau, Moritz
    Dreger, Peter
    Ritgen, Matthias
    Illmer, Thomas
    Illert, Anna Lena
    Duerig, Jan
    Boettcher, Sebastian
    Niemann, Carsten Utoft
    Kneba, Michael
    Fink, Anna-Maria
    Fischer, Kirsten
    Doehner, Hartmut
    Hallek, Michael
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    BLOOD, 2022, 140
  • [22] Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL
    Gibiansky, E.
    Gibiansky, L.
    Carlile, Dj
    Jamois, C.
    Buchheit, V.
    Frey, N.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (10):
  • [23] Final Analysis of the Prospective Multicenter CLL2- GIVe Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
    Huber, H.
    Edenhofer, S.
    von, Tresckow J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 10
  • [24] Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Bosch, Francesc
    Illmer, Thomas
    Turgut, Mehmet
    Cortelezzi, Agostino
    Lasserre, Susan F.
    Truppel-Hartmann, Anna
    Leblond, Veronique
    Foa, Robin
    Stilgenbauer, Stephan
    BLOOD, 2014, 124 (21)
  • [25] CLL2-BIG - A Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients With Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 19 - 21
  • [26] CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial
    von Tresckow, Julia
    Cramer, Paula
    Bahlo, Jasmin
    Robrecht, Sandra
    Engelke, Anja
    Langerbeins, Petra
    Fink, Anna-Maria
    Illmer, Thomas
    Klaproth, Holger
    Estenfelder, Sven
    Ritgen, Matthias
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Bottcher, Sebastian
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [27] Early results of modified fludarabine, cyclophosphamide, and rituximab (mFCR) for patients with previously untreated advanced chronic lymphocytic leukemia (CLL).
    Tarhini, A. A.
    Land, S.
    Lim, F.
    Kiefer, G. J.
    Pietragallo, L.
    Pinkerton, R. A.
    Sulecki, M.
    Meisner, D.
    Schaefer, P. M.
    Foon, K. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [28] Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study
    Leblond, Veronique
    Cantin, Guy
    Cortelezzi, Agostino
    Knauf, Wolfgang
    Tiab, Mourad
    Turgut, Mehmet
    Zaritskey, Andrey
    Merot, Jean-Louis
    Trunzer, Kerstin
    Robson, Susan
    Gresko, Ekaterina
    Stilgenbauer, Stephan
    Foa, Robin
    Bosch, Francesc
    BLOOD, 2017, 130
  • [29] Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)
    Von Tresckow, Julia
    Cramer, Paula
    De Silva, Nisha
    Bahlo, Jasmin
    Robrecht, Sandra
    Langerbeins, Petra
    Fink, Anna-Maria
    Al-Sawaf, Othman
    Furstenau, Moritz
    Illmer, Thomas
    Klaproth, Holger
    Tausch, Eugen
    Ritgen, Matthias
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2019, 134
  • [30] CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial
    von Tresckow, Julia
    Cramer, Paula
    Bahlo, Jasmin
    Engelke, Anja
    Langerbeins, Petra
    Fink, Anna-Maria
    Klaproth, Holger
    Tausch, Eugen
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2015, 126 (23)
12345